Exelixis Inc.

Exelixis is an oncology-focused biotechnology company that involved in the discovery, development and commercialization of new medicines for cancers. The company's marketd products are: CABOMETYX? (cabozantinib) tablets for renal cell carcinoma and previously treated hepatocellular carcinoma; and COMETRIQ? (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer. The company's products resulting from its discovery efforts are: COTELLIC? (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat melanoma; and MINNEBRO? (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
  • TickerEXEL
  • ISINUS30161Q1040
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
EXEL EXELIXIS INC. (Health Care)

EXELIXIS loses on its star level and is downgraded to Slightly Positiv...

The independent financial analyst theScreener just slightly lowered the general evaluation of EXELIXIS (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 22.95 and its potential was estimated at USD 27.61.

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share A...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology indications, making the case for a moat more difficult with so many therapies vying for first-line shar...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis is best known for its discovery of cabozantinib, a tyrosine kinase inhibitor (TKI) that was first approved in 2012 for medullary thyroid cancer (MTC). The small molecule was later approved in renal cell carcinoma (RCC), as well as hepatocellular carcinoma (HCC). The cabo opportunity has room to grow further, with late-stage trials in differentiated thyroid cancer (DTC) and in immuno-oncology combinations. Although we anticipate robust returns from cabozantinib, we believe the long-term outlook is uncertain given the company's pipeline outside of cabo, which is early-stage and relative...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis reported a solid first quarter, with total revenue of $215.5 million, essentially flat from last year, and operating expenses ramping up in line with our expectations as the company has several late-stage trials ongoing. We don't anticipate any changes to our fair value estimate of $28 per share, and we are maintaining our no-moat rating for Exelixis. Cabometyx, approved in kidney cancer and second-line liver cancer, contributed nearly $176 million, up 36% from last year and 2.5% sequen...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share After Fresh Loo...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology ind...

EXEL EXELIXIS INC. (Health Care)

EXELIXIS loses on its star level and is downgraded to Slightly Positiv...

The independent financial analyst theScreener just slightly lowered the general evaluation of EXELIXIS (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 22.95 and its potential was estimated at USD 27.61.

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share A...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology indications, making the case for a moat more difficult with so many therapies vying for first-line shar...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis is best known for its discovery of cabozantinib, a tyrosine kinase inhibitor (TKI) that was first approved in 2012 for medullary thyroid cancer (MTC). The small molecule was later approved in renal cell carcinoma (RCC), as well as hepatocellular carcinoma (HCC). The cabo opportunity has room to grow further, with late-stage trials in differentiated thyroid cancer (DTC) and in immuno-oncology combinations. Although we anticipate robust returns from cabozantinib, we believe the long-term outlook is uncertain given the company's pipeline outside of cabo, which is early-stage and relative...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis reported a solid first quarter, with total revenue of $215.5 million, essentially flat from last year, and operating expenses ramping up in line with our expectations as the company has several late-stage trials ongoing. We don't anticipate any changes to our fair value estimate of $28 per share, and we are maintaining our no-moat rating for Exelixis. Cabometyx, approved in kidney cancer and second-line liver cancer, contributed nearly $176 million, up 36% from last year and 2.5% sequen...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share After Fresh Loo...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology ind...

EXEL EXELIXIS INC. (Health Care)

EXELIXIS loses on its star level and is downgraded to Slightly Positiv...

The independent financial analyst theScreener just slightly lowered the general evaluation of EXELIXIS (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 22.95 and its potential was estimated at USD 27.61.

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share A...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology indications, making the case for a moat more difficult with so many therapies vying for first-line shar...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis is best known for its discovery of cabozantinib, a tyrosine kinase inhibitor (TKI) that was first approved in 2012 for medullary thyroid cancer (MTC). The small molecule was later approved in renal cell carcinoma (RCC), as well as hepatocellular carcinoma (HCC). The cabo opportunity has room to grow further, with late-stage trials in differentiated thyroid cancer (DTC) and in immuno-oncology combinations. Although we anticipate robust returns from cabozantinib, we believe the long-term outlook is uncertain given the company's pipeline outside of cabo, which is early-stage and relative...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis reported a solid first quarter, with total revenue of $215.5 million, essentially flat from last year, and operating expenses ramping up in line with our expectations as the company has several late-stage trials ongoing. We don't anticipate any changes to our fair value estimate of $28 per share, and we are maintaining our no-moat rating for Exelixis. Cabometyx, approved in kidney cancer and second-line liver cancer, contributed nearly $176 million, up 36% from last year and 2.5% sequen...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share After Fresh Loo...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology ind...

EXEL EXELIXIS INC. (Health Care)

EXELIXIS loses on its star level and is downgraded to Slightly Positiv...

The independent financial analyst theScreener just slightly lowered the general evaluation of EXELIXIS (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 22.95 and its potential was estimated at USD 27.61.

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share A...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology indications, making the case for a moat more difficult with so many therapies vying for first-line shar...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis is best known for its discovery of cabozantinib, a tyrosine kinase inhibitor (TKI) that was first approved in 2012 for medullary thyroid cancer (MTC). The small molecule was later approved in renal cell carcinoma (RCC), as well as hepatocellular carcinoma (HCC). The cabo opportunity has room to grow further, with late-stage trials in differentiated thyroid cancer (DTC) and in immuno-oncology combinations. Although we anticipate robust returns from cabozantinib, we believe the long-term outlook is uncertain given the company's pipeline outside of cabo, which is early-stage and relative...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis reported a solid first quarter, with total revenue of $215.5 million, essentially flat from last year, and operating expenses ramping up in line with our expectations as the company has several late-stage trials ongoing. We don't anticipate any changes to our fair value estimate of $28 per share, and we are maintaining our no-moat rating for Exelixis. Cabometyx, approved in kidney cancer and second-line liver cancer, contributed nearly $176 million, up 36% from last year and 2.5% sequen...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share After Fresh Loo...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology ind...

EXEL EXELIXIS INC. (Health Care)

EXELIXIS loses on its star level and is downgraded to Slightly Positiv...

The independent financial analyst theScreener just slightly lowered the general evaluation of EXELIXIS (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 22.95 and its potential was estimated at USD 27.61.

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share A...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology indications, making the case for a moat more difficult with so many therapies vying for first-line shar...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Morningstar | Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis is best known for its discovery of cabozantinib, a tyrosine kinase inhibitor (TKI) that was first approved in 2012 for medullary thyroid cancer (MTC). The small molecule was later approved in renal cell carcinoma (RCC), as well as hepatocellular carcinoma (HCC). The cabo opportunity has room to grow further, with late-stage trials in differentiated thyroid cancer (DTC) and in immuno-oncology combinations. Although we anticipate robust returns from cabozantinib, we believe the long-term outlook is uncertain given the company's pipeline outside of cabo, which is early-stage and relative...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share

Exelixis reported a solid first quarter, with total revenue of $215.5 million, essentially flat from last year, and operating expenses ramping up in line with our expectations as the company has several late-stage trials ongoing. We don't anticipate any changes to our fair value estimate of $28 per share, and we are maintaining our no-moat rating for Exelixis. Cabometyx, approved in kidney cancer and second-line liver cancer, contributed nearly $176 million, up 36% from last year and 2.5% sequen...

Anna Baran
  • Anna Baran
EXEL EXELIXIS INC. (Health Care)

Lowering Our FVE for No-Moat Exelixis to $24 Per Share After Fresh Loo...

After taking a fresh look at Exelixis, we are revising our fair value estimate downward to $24 per share after adjusting our patient share expectations, modeling in cabozantinib generic entry, and increasing near-term operating expenses. We're reiterating our no-moat rating for the biotech. Even though we expect robust returns from the cabozantinib franchise, we believe the company's heavy reliance on one molecule precludes an economic moat. Further, cabozantinib competes in crowded oncology ind...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch